UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001964
Receipt number R000002376
Scientific Title Ocular hypotensive effects of TAPROS ophthalmic solution 0.0015%.
Date of disclosure of the study information 2009/05/14
Last modified on 2009/11/16 13:56:24

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Ocular hypotensive effects of TAPROS ophthalmic solution 0.0015%.

Acronym

Ocular hypotensive effects of TAPROS ophthalmic solution 0.0015%.

Scientific Title

Ocular hypotensive effects of TAPROS ophthalmic solution 0.0015%.

Scientific Title:Acronym

Ocular hypotensive effects of TAPROS ophthalmic solution 0.0015%.

Region

Japan


Condition

Condition

Glaucoma

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate ocular hypotensive effects of TAPROS ophthalmic solution 0.0015% in Glaucoma patients, not enough hypotensive effect with other prostaglandin ophthalmic solution.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Intraocular pressure reduction,
% reduction of intraocular pressure.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

TAPROS ophthalmic solution 0.0015%

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit

90 years-old >=

Gender

Male and Female

Key inclusion criteria

1)Patients, over 18mmHg in intra ocular pressure, at least 4weeks Xalatan TM ophthalmic solution treatment and at least 4weeks Travatan z TM ophthalmic solution treatment.
2)Patients, without 20% ocular hypotensive effects, at least 4weeks Xalatan TM ophthalmic solution treatment and at lease 4weeks Travatan z TM ophthalmic solution treatment.
3)Patients, be graded under stage4 at Kozaki's classification.

Key exclusion criteria

1)Presence of any external disease and inflammation of the eye.
2)History of intraocular surgery within one month.
3)Patients with Drug-induced hypersensitivity syndrome.
4)Patients with maintain over 35mmHg in intraocular pressure over one week.
5) The investigator declares any subject ineligible for any sound medical reason.

Target sample size

10


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Shiniciro Ishikawa

Organization

Saga University Faculty of Medicine

Division name

Department of Ophthalmology

Zip code


Address

Nabeshima 5-1-1, Saga, Saga, 849-8501

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Saga University Faculty of Medicine

Division name

Department of Ophthalmology

Zip code


Address

Nabeshima 5-1-1, Saga, Saga, 849-8501

TEL


Homepage URL


Email



Sponsor or person

Institute

Department of Ophthalmology, Saga University Faculty of Medicine

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2009 Year 05 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2008 Year 12 Month 07 Day

Date of IRB


Anticipated trial start date

2008 Year 12 Month 01 Day

Last follow-up date

2010 Year 05 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2009 Year 05 Month 13 Day

Last modified on

2009 Year 11 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002376


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name